Day: July 8, 2020

DRAPER, Utah, July 08, 2020 (GLOBE NEWSWIRE) — HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”), today announced the pricing of the previously announced underwritten public offering of shares of its common stock. HealthEquity has agreed to sell an aggregate of 4,600,000 shares of its common stock at a price to the public of $56.00 per share.  Gross proceeds to HealthEquity from the offering are expected to be $257,600,000. The offering is expected to close on July 13, 2020, subject to customary closing conditions. Additionally, HealthEquity has granted the underwriters a 30-day option to purchase up to an additional 690,000 shares of its common stock.  HealthEquity intends to use the net proceeds from the offering to free up additional capital for organic and inorganic growth by pre-paying $200 million under its...

First large study in constitutional genetic diseases showed 100% concordance to gold-standard cytogenetic testingIn patients with leukemia, Saphyr enabled crucial discoveries including novel fusion events never described before in that diseaseSaphyr solved previously unidentified genetic diseases by finding novel mutationsMaking continued progress on goal to become the new standard of digital cytogenetic testingSAN DIEGO, July 08, 2020 (GLOBE NEWSWIRE) — Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that two top cytogeneticists from leading institutions in The Netherlands and France presented their research data as part of a multicentric, international effort to compare data generated with Bionano’s Saphyr system against gold standard cytogenetic methods consisting of karyotyping, FISH, and/or chromosomal microarray in patients...

SAN DIEGO, July 08, 2020 (GLOBE NEWSWIRE) — American Assets Trust, Inc. (NYSE:AAT) (the “Company”) will announce its second quarter 2020 earnings in a press release to be issued after the market closes on Tuesday, July 28, 2020.Senior management will hold a conference call for its second quarter 2020 earnings on Wednesday, July 29, 2020 at 8:00 a.m. Pacific Time (“PT”).  Conference call access information is as follows:Toll Free Number: 1 (877) 868-5513Pass Code: 4494304A telephonic replay of the conference call will be available beginning at 2:00 p.m. PT on Wednesday, July 29, 2020 through Wednesday, August 5, 2020.  Replay access information is as follows:Toll Free Number: 1 (855) 859-2056Pass Code: 4494304About American Assets Trust, Inc.                                                  American Assets Trust, Inc. is a full service,...

Daix (France), July 8, 2020 – Inventiva (Euronext Paris: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (“NASH”), mucopolysaccharidoses (“MPS”) and other diseases with significant unmet medical need, today announced the formal commencement of bookbuilding and the filing of an amended registration statement on Form F-1, including an estimated initial public offering price range, in connection with its intention to issue and sell, subject to market and other conditions, a total of 7,478,261 ordinary shares of the Company in an initial public offering of American Depositary Shares (“ADSs”), each representing one ordinary share, in the United States (the “U.S. Offering”) and a concurrent offering...

Daix (France), le 8 Juillet 2020 – Inventiva (Euronext Paris: IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement clinique de petites molécules administrées par voie orale pour le traitement de la stéatohépatite non alcoolique (« NASH »), des mucopolysaccharidoses (« MPS ») et d’autres maladies avec un besoin médical non satisfait significatif, annonce aujourd’hui le début formel de la procédure de construction du livre d’ordres et le dépôt d’un « amendment » (avenant) au document d’enregistrement (Form F-1) pour y inclure une fourchette de prix indicative dans le cadre de son projet d’offre, sous réserve notamment des conditions de marché, d’un total de 7 478 261 actions ordinaires de la Société. Ce projet d’offre comprend une offre d’American Depositary...

PLEASANTON, Calif., July 08, 2020 (GLOBE NEWSWIRE) — 10x Genomics (Nasdaq: TXG) today announced it will report financial results for the second quarter 2020 after market close on Tuesday, August 11, 2020. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook.Live audio of the webcast will be available on the “Investors” section of the company website at: www.10xgenomics.com. The webcast will be archived and available for replay for at least 45 days after the event.About 10x Genomics10x Genomics is a life science technology company building products to interrogate, understand and master biology to advance human health. The company’s integrated solutions include instruments, consumables and software...

CHATTANOOGA, Tenn., July 08, 2020 (GLOBE NEWSWIRE) — Covenant Logistics Group, Inc. (NASDAQ/GS: CVLG) (“Covenant”) today announced the sale of the transportation factoring assets of its Transport Financial Solutions (“TFS”) segment to Triumph Business Capital for approximately $132.2 million, including contingent consideration of approximately $9.9 million. Triumph Business Capital is an indirect wholly owned subsidiary of Triumph Bancorp, Inc. (NASDAQ: TBK) (“Triumph”).Chairman and Chief Executive Officer, David R. Parker, commented: “TFS has grown significantly since inception in late 2011 and delivered consistently strong margins and returns. With a critical mass of over $100.0 million of capital deployed and strong growth opportunities, it was time to transition the business to an owner with a core lending focus and deep knowledge...

DALLAS, July 08, 2020 (GLOBE NEWSWIRE) — Triumph Bancorp, Inc. (Nasdaq: TBK) (the “Company”) announced today the close of the acquisition of the transportation factoring assets of Transport Financial Solutions (“TFS”) by Triumph Business Capital.  Triumph Business Capital is an indirect wholly owned subsidiary of the Company. TFS is a wholly owned subsidiary of Covenant Logistics Group, Inc. (Nasdaq/GS: CVLG) (“Covenant”).The transaction was structured as the acquisition of TFS’ factoring assets, consisting primarily of $103.3 million of net accounts receivable and related transportation factoring assets, in exchange for closing cash consideration of $108.4 million, plus Company common stock valued at approximately $13.9 million.  In addition, TFS has the opportunity to earn contingent cash consideration of up to approximately $9.9...

VANCOUVER, Washington, July 08, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn, and Scott Kelly, M.D., Chief Medical Officer of CytoDyn, will provide a comprehensive business and clinical trials update. The Wall Street Reporter’s event is scheduled for Thursday, July 9, 2020 at 1:30 pm ET / 10:30 am PT. The presentation will be approximately 15 minutes followed by a Q&A session of approximately 45 minutes.Interested participants are encouraged to login early prior to the start of the event. Please note that there will be no telephone access; this is a webcast...

CALGARY, Alberta, July 08, 2020 (GLOBE NEWSWIRE) — Enerflex Ltd. (TSX:EFX) (“Enerflex” or the “Company”), a leading supplier of products and services to the global energy industry, will release its second quarter 2020 financial results on August 6, 2020. These results will be available on the Enerflex website at www.enerflex.com.Analysts, investors, members of the media, and other interested parties are invited to participate in a teleconference and audio webcast on Friday, August 7, 2020 at 8:00 a.m. MDT to discuss the second quarter 2020 financial results and operating highlights.To participate, please call toll free 1.844.231.9067 or 1.703.639.1277. Please dial in 10 minutes prior to the start of the call. No passcode is required. The live audio webcast of the teleconference will be available on the Enerflex website at www.enerflex.com...